Contract Organizations are the Sell of the Season - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Contract Organizations are the Sell of the Season
Despite the market downturn, private equity investors are lining up for pharmaceutical services.


Pharmaceutical Technology
Volume 33, Issue 4, pp. 82-84

More to come

Private equity investors may get another bite of the top 10 CRO apple in coming months if the directors of MDS (Toronto), the parent company of MDS Pharmaceutical Services (MDSPS), decide to test the market. MDS has formed a committee of independent directors to review alternative ways to improve shareholder value.

Like PharmaNet, MDSPS, which had revenues of $482 million in 2008, has faced some particular challenges. Its early development business has been hurt by the reputational and operational implications of quality problems at its Montreal bioanalytical laboratory, which was cited by the US Food and Drug Administration in 2004 for inadequate investigation of contaminated samples. MDSPS' management reports that the problems are largely resolved and that the company is attracting clients back to the bioanalytical business. In the Phase II–IV segment, however, MDSPS continues to lose market share to larger competitors, including Quintiles Transnational (Research Triangle Park, NC), PPD (Wilmington, NC), Icon (Dublin), and Parexel (Waltham, MA). The company also suffers from a smaller scale and a more limited global footprint, even though its revenues put it among the top 10 CROs.

MDS has ample cash and little longterm debt, so it is not compelled to sell. However, its board and management have been under investor pressure to consider strategic alternatives. With three distinct businesses in its portfolio (MDS also has business units that make analytical instruments and radiopharmaceuticals), the company does have some interesting options, including selling one or more of its business units to strategic or private equity buyers.

Still picky

Although publicly held CROs represent the highest profile targets for current investment, we are aware of several well-known privately-held CMOs whose owners have put them on the block and which are attracting considerable interest from investors. Private investors aren't the only buyers, either. Publicly-held CROs such as PPD, which recently acquired the Eastern European CRO AbCRO, are also taking the opportunity to pursue deals that flesh out their capabilities.

This doesn't mean investors aren't being picky, however. Many investors are focused on CROs with strong market positions and viable business models, mindful that the services industry will experience a shakeout in the coming months.

The lesson here is that despite the doom and gloom in the financial media, there are still good businesses to invest in and institutions with money to invest in them. The smart money seems to be saying that pharmaceutical services will be a great business well into the future.

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905,
, http://www.pharmsource.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here